Ng Bernardo, Postlethwaite Alejandra, Rollnik Jens
UCSD Department of Psychiatry, Sun Valley Behavioral Medical Center, Irvine, California, USA.
Int Clin Psychopharmacol. 2003 Jan;18(1):57-9. doi: 10.1097/00004850-200301000-00010.
Premarketing trials of olanzapine reported an incidence of peripheral oedema of 3%. Outpatients, who were actively receiving treatment with olanzapine, were evaluated for peripheral oedema. Twenty-eight (57%) out of 49 subjects exhibited oedema, including five (10.2%) to a severe degree. There were no significant differences regarding gender, time/dose on olanzapine, concomitant diagnoses or psychotropic medication. There was a tendency (P < 0.10) for older age and greater frequency of thyroid abnormalities in those individuals with oedema. In the oedema group, there was a positive correlation (P < 0.05) between age and severity. Our finding, far from demonstrating that olanzapine causes oedema at this frequency, suggests that there maybe patients who are vulnerable to developing this side-effect.
奥氮平的上市前试验报告外周水肿的发生率为3%。对正在接受奥氮平积极治疗的门诊患者进行外周水肿评估。49名受试者中有28名（57%）出现水肿，其中5名（10.2%）为重度水肿。在性别、奥氮平治疗时间/剂量、伴发诊断或精神药物方面无显著差异。水肿患者中，年龄较大和甲状腺异常频率较高有一定趋势（P<0.10）。在水肿组中，年龄与严重程度之间存在正相关（P<0.05）。我们的发现远未表明奥氮平以这种频率导致水肿，而是表明可能有患者易发生这种副作用。
